Mogamulizumab, which is branded as ‘POTELIGEO Injection’, is a novel, humanized monoclonal antibody directed against CC chemokine receptor 4 (CCR4), which is over-expressed on various malignant T cells,
Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases. Magnum’s facilities include a clinic
The move follows an approval from the European Commission in November 2013. Currently, Abilify Maintena is available in several European countries and is progressing through the various Healthcare
Under the deal, BMS will use Five Prime’s platform to move forward its existing immuno-oncology programs by identifying the most viable drug targets for continued research and development.
If successful, both companies will collaborate on developing the imaging flow technology platform for future commercialization in hematology. Currently, Sysmex is conducting a clinical study assessing EMD Millipore’s
The company is developing EPI-743 for pediatric and adult mitochondrial disease, including Friedreich’s ataxia. In the recently completed Phase I and multiple Phase II trials, EPI-743 has been
Findings from a pre-specified retrospective analysis of patients showed that talimogene laherparepvec reduced the size of injected tumors and also non-injected tumors that had metastasized to other parts
The antifungal agent is also marketed as NOXAFIL (100mg) delayed-release tablets and NOXAFIL (40 mg/mL) oral suspension. The company said that NOXAFIL injection, delayed-release tablets and oral suspension
The patent includes claims to protect the use of a clinical-stage drug candidate BL-8040’s composition for improving immune responses to an antigen, such as a tumor-associated antigen. The
The pivotal Phase III POISE trial showed that OCA, at both a 10mg dose and a 5mg dose titrated to 10mg, met the trial’s primary endpoint of achieving
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.